Kamada Ltd. (NASDAQ:KMDA) Sees Large Decline in Short Interest

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 35,100 shares, a decrease of 78.9% from the February 13th total of 166,100 shares. Based on an average daily volume of 194,200 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.

Kamada Price Performance

Shares of KMDA traded down $0.11 during trading hours on Thursday, hitting $7.23. The company’s stock had a trading volume of 57,896 shares, compared to its average volume of 255,067. The company has a market cap of $415.58 million, a price-to-earnings ratio of 25.82, a PEG ratio of 0.97 and a beta of 0.97. The business has a 50 day simple moving average of $7.20 and a two-hundred day simple moving average of $6.20. Kamada has a 52-week low of $4.74 and a 52-week high of $9.15.

Kamada Dividend Announcement

The business also recently declared a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be given a $0.20 dividend. The ex-dividend date is Monday, March 17th.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, March 6th.

Institutional Trading of Kamada

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. purchased a new position in Kamada during the 4th quarter valued at about $67,000. Public Employees Retirement System of Ohio bought a new position in shares of Kamada during the third quarter valued at about $77,000. Plato Investment Management Ltd purchased a new position in shares of Kamada in the third quarter worth about $117,000. NewEdge Advisors LLC increased its holdings in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after buying an additional 8,260 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.